

FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products.

August 7, 2024

FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024;

<https://psnet.ahrq.gov/issue/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded>

Patient-administered medications can lead to a [variety](#) of errors that have the potential to harm. This announcement raises awareness of the potential for [dosing errors](#) due to [measurement mistakes](#) of injectable medications and reviews reported adverse events and hospitalizations associated with the errors.